Experts are uncertain about the outcome of the DOJ's recent lawsuit regarding the UnitedHealth Group/Amedisys merger, especially under the Trump administration's approach to antitrust cases.
While the Biden administration has been supportive of clinicians, the Trump administration tended to favor corporate interests in antitrust matters, which complicates predictions for this case.
This antitrust lawsuit stands apart from typical cases, as it does not appear to center around the potential for price increases, which is often a focal point for such actions.
Collection
[
|
...
]